Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/03/2022* -- Results Q3 2022 -- 5.93 --
11/03/2022* 08:30 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 -0.68 -0.39 -72.88%
08/03/2022 08:30 EST Earnings Call Q2 2022 -- -- --
05/06/2022 -- Results Q1 2022 -0.58 -0.76 23.28%
05/06/2022 08:30 EST Earnings Call Q1 2022 -- -- --
03/02/2022 -- Results Q4 2021 -1.23 -0.81 -51.85%
03/02/2022 08:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/03/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since 20.66%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
URL https://www.interceptpharma.com
Investor Relations URL https://ir.interceptpharma.com/
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-4.26%
-27.25%
-46.23%
72.53%
22.95%
-80.07%
-34.05%
2.52%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-10.85%
--
--
--
37.06%
47.21%
57.44%
60.79%
6.75%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-13.42%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
1.58%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
18.37%
As of August 10, 2022.

Profile

Edit
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
URL https://www.interceptpharma.com
Investor Relations URL https://ir.interceptpharma.com/
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CIG4926 10.33M USD 5.45%
F000015ZK6 230.00 USD 2.30%
FTMSX 192304.0 USD 1.60%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ICPT Tweets